Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction
Oscar Bartulos, … , Jordan S. Pober, Yibing Qyang
Oscar Bartulos, … , Jordan S. Pober, Yibing Qyang
Published July 7, 2016
Citation Information: JCI Insight. 2016;1(10):e80920. https://doi.org/10.1172/jci.insight.80920.
View: Text | PDF
Research Article Cardiology Neuroscience Stem cells Transplantation Vascular biology

ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction

  • Text
  • PDF
Abstract

Cardiovascular progenitor cells (CPCs) expressing the ISL1-LIM–homeodomain transcription factor contribute developmentally to cardiomyocytes in all 4 chambers of the heart. Here, we show that ISL1-CPCs can be applied to myocardial regeneration following injury. We used a rapid 3D methylcellulose approach to form murine and human ISL1-CPC spheroids that engrafted after myocardial infarction in murine hearts, where they differentiated into cardiomyocytes and endothelial cells, integrating into the myocardium and forming new blood vessels. ISL1-CPC spheroid–treated mice exhibited reduced infarct area and increased blood vessel formation compared with control animals. Moreover, left ventricular (LV) contractile function was significantly better in mice transplanted with ISL1-CPCs 4 weeks after injury than that in control animals. These results provide proof-of-concept of a cardiac repair strategy employing ISL1-CPCs that, based on our previous lineage-tracing studies, are committed to forming heart tissue, in combination with a robust methylcellulose spheroid–based delivery approach.

Authors

Oscar Bartulos, Zhen Wu Zhuang, Yan Huang, Nicole Mikush, Carol Suh, Alda Bregasi, Lin Wang, William Chang, Diane S. Krause, Lawrence H. Young, Jordan S. Pober, Yibing Qyang

×

Figure 11

Human ISL1-CPC spheroids produced growth factors with antifibrotic properties.

Options: View larger image (or click on image) Download as PowerPoint
Human ISL1-CPC spheroids produced growth factors with antifibrotic prope...
(A) SMA staining in human adult ventricular cardiac fibroblasts, 48 hours after treatment with the indicated growth factors. Scale bars: 50 μm. Graph showing reduced numbers of human cardiac fibroblasts with SMA+ filament bundle formation, 48 hours after treatment with NRG1β or ANGPT1. n = 4 (paired 2-tailed Student’s t test, *P < 0.05, **P < 0.01). (B) Western blots and graph quantification showing that NRG1β and ANGPT1 reduced collagen 1a1 protein and that NRG1β reduced SMA in human adult ventricular cardiac fibroblasts. n = 4 (paired 2-tailed Student’s t test, *P < 0.05).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts